FFA
SPRO icon

Farther Finance Advisors’s Spero Therapeutics SPRO Stock Holding History

Farther Finance Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22 Hold
10
– – ﹤0.01% 5897
2026
Q1 		$25 Hold
10
– – ﹤0.01% 5631
2025
Q4 		$23 Buy
+10
New +$23 ﹤0.01% 5390

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Farther Finance Advisors's SPRO Position: Q2 2026 in Review

Farther Finance Advisors held its Spero Therapeutics (SPRO) position steady in Q2 2026 at 10 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #5897.

Farther Finance Advisors first reported a position in SPRO in Q4 2025 and has held it in 3 quarters since. The position peaked at $25 in Q1 2026. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Farther Finance Advisors held 10 shares of Spero Therapeutics worth $22 as of Q2 2026.
  • Farther Finance Advisors left its Spero Therapeutics share count unchanged in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5897 holding.
  • Farther Finance Advisors first reported a position in Spero Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Farther Finance Advisors's Spero Therapeutics position peaked at $25 in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.